<DOC>
	<DOCNO>NCT00989014</DOCNO>
	<brief_summary>This randomize , double-blind , parallel-group , vehicle-controlled , dose-finding study investigate pharmacodynamics safety three dosage CD07805/47 topical gel ( 0.07 % , 0.18 % , 0.50 % ) , single application subject clinical diagnosis stable moderate severe erythematotelangiectatic rosacea . Subjects randomize 1:1:1:1 ratio receive either one three CD07805/47 topical gel concentration ( 0.07 % , 0.18 % , 0.50 % ) Vehicle Gel . All subject treat single application ( daily dose one day ) study medication .</brief_summary>
	<brief_title>Dose-Finding Study CD07805/47 Topical Gel Subjects With Erythematotelangiectatic Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<criteria>Male female least 18 year age . Clinical diagnosis stable moderate severe erythematotelangiectatic rosacea . CEA ( clinician 's erythema assessment ) score great equal 3 Screening Treatment visit baseline . PSA ( patient self assessment ) score great equal 3 Screening Treatment visit baseline . Presence 2 few inflammatory facial lesion . History Raynaud 's Syndrome , glaucoma , orthostatic hypotension , thromboangiitis obliterans , cerebral coronary insufficiency , depression . History refractive surgery photorefractive keratectomy . The subject treat monoamine oxidase ( MAO ) inhibitor , antidepressant , barbiturate , opiate , sedative , systemic anesthetic , alphaagonists , beta blocker , antihypertensive agent , cardiac glycoside , systemic anticoagulant . The subject currently enrol investigational drug device study participate study past 3 month prior enrollment still exclusion period day Treatment visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Erythematotelangiectatic</keyword>
	<keyword>Rosacea</keyword>
</DOC>